| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
C22-Ceramide is an endogenous bioactive sphingolipid that functions as a structural component of cell membranes. It interacts with other ceramides to modulate membrane properties and signaling pathways. Specifically, C22-Ceramide reduces the propensity of C16-ceramide channel formation in mitochondrial membranes. This interaction suggests a role in regulating ceramide-mediated apoptosis and mitochondrial function. Its targets include membrane lipids and components of the ceramide signaling pathway.
|
|---|---|
| ln Vitro |
In vitro, C22-Ceramide reduces the propensity of C16-ceramide channel formation in isolated rat liver mitochondria and in liposomes. This activity suggests a role in modulating ceramide-mediated membrane permeability and mitochondrial function. The compound's effects on membrane properties have been characterized in liposome and mitochondrial model systems. It has been studied for potential therapeutic applications in skin disorders, cancer, and neurodegenerative diseases.
|
| ln Vivo |
In vivo, C22-Ceramide is an endogenous lipid that plays a role in cell membrane structure and signaling. It has been studied for potential therapeutic applications in treating skin disorders, such as atopic dermatitis, and its role in cancer and neurodegenerative diseases, where ceramide metabolism is often dysregulated. The compound's in vivo effects are related to its role in maintaining membrane integrity and modulating ceramide signaling pathways.
|
| Enzyme Assay |
Non-cellular assays for C22-Ceramide would involve membrane model systems to study its effects on membrane properties. Liposome permeability assays can be used to assess the compound's ability to modulate C16-ceramide channel formation. Isolated mitochondrial assays can be performed to evaluate effects on mitochondrial membrane permeability. Lipid bilayer electrophysiology studies could be used to characterize channel formation.
|
| Cell Assay |
Cell-based assays for C22-Ceramide would involve studying its effects on ceramide signaling and cell function. The compound's effects on apoptosis, cell proliferation, and membrane integrity could be assessed in various cell lines. Its role in ceramide metabolism and signaling could be studied using lipidomics and signaling pathway analysis. Specific protocols for these assays are not extensively documented in the available literature.
|
| Animal Protocol |
In vivo animal studies for C22-Ceramide would typically involve models of skin disorders, cancer, or neurodegenerative diseases. The compound's effects on skin barrier function, tumor growth, or neuroprotection could be assessed in relevant animal models. Pharmacokinetic and toxicity studies in relevant animal models would also be conducted. Specific protocols for these studies are not extensively documented in the search results.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for C22-Ceramide have not been reported in the available literature. As a sphingolipid with a molecular weight of 622.06 g/mol, it is a highly lipophilic compound. Its absorption, distribution, metabolism, and excretion would be influenced by its lipid nature. No specific pharmacokinetic parameters have been characterized for this compound.
|
| Toxicity/Toxicokinetics |
No toxicity data have been reported for C22-Ceramide in the available literature. As an endogenous sphingolipid, it is generally considered to have a favorable safety profile, though systematic toxicological evaluation has not been performed. The compound is for research use only and is not for human therapeutic use. Standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
N-Chocoylsphingosine is an N-acylsphingosine in which the N-acyl group of the ceramide is definitively defined as a docosacyl group. It is a mouse metabolite. It is an N-acylsphingosine and also a Cer(d40:1). Functionally, it is associated with docosaccharide. N-Chocoylsphingosine has been reported to be detected in Trypanosoma brevicornu, and relevant data are available.
C22-Ceramide is a research compound, not an approved pharmaceutical drug. It is an endogenous bioactive sphingolipid that is an essential component of cell membranes. The compound reduces the propensity of C16-ceramide channel formation in mitochondria and liposomes. It has been studied for potential therapeutic applications in treating skin disorders, such as atopic dermatitis, and its role in cancer and neurodegenerative diseases. C22-Ceramide is for research use only. |
| Molecular Formula |
C40H79NO3
|
|---|---|
| Molecular Weight |
622.06
|
| Exact Mass |
621.606
|
| CAS # |
27888-44-4
|
| PubChem CID |
5283567
|
| Appearance |
White to off-white solid powder
|
| LogP |
12.294
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
36
|
| Heavy Atom Count |
44
|
| Complexity |
593
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@@H](/C=C/CCCCCCCCCCCCC)O
|
| InChi Key |
KEPQASGDXIEOIL-GLQCRSEXSA-N
|
| InChi Code |
InChI=1S/C40H79NO3/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-24-26-28-30-32-34-36-40(44)41-38(37-42)39(43)35-33-31-29-27-25-23-16-14-12-10-8-6-4-2/h33,35,38-39,42-43H,3-32,34,36-37H2,1-2H3,(H,41,44)/b35-33+/t38-,39+/m0/s1
|
| Chemical Name |
N-[(E,2S,3R)-1,3-dihydroxyoctadec-4-en-2-yl]docosanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMF: 0.33 mg/mL (0.53 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6076 mL | 8.0378 mL | 16.0756 mL | |
| 5 mM | 0.3215 mL | 1.6076 mL | 3.2151 mL | |
| 10 mM | 0.1608 mL | 0.8038 mL | 1.6076 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
